Eli Lilly and Company
LLY
$989.87
$22.882.37%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 47.44% | 44.71% | 45.41% | 36.83% | 36.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.44% | 44.71% | 45.41% | 36.83% | 36.38% |
| Cost of Revenue | 38.30% | 31.30% | 29.25% | 23.43% | 25.82% |
| Gross Profit | 49.48% | 47.79% | 49.23% | 40.03% | 38.99% |
| SG&A Expenses | 26.45% | 30.32% | 37.73% | 34.53% | 29.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.89% | 27.09% | 27.69% | 23.61% | 21.86% |
| Operating Income | 73.75% | 73.65% | 76.31% | 60.67% | 66.04% |
| Income Before Tax | 128.86% | 102.93% | 121.69% | 87.55% | 79.87% |
| Income Tax Expenses | 134.51% | 143.60% | 129.77% | 85.75% | 75.30% |
| Earnings from Continuing Operations | 127.59% | 94.90% | 119.98% | 87.95% | 80.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 127.59% | 94.90% | 119.98% | 87.95% | 80.93% |
| EBIT | 73.75% | 73.65% | 76.31% | 60.67% | 66.04% |
| EBITDA | 68.45% | 67.95% | 69.99% | 56.16% | 60.28% |
| EPS Basic | 128.75% | 95.78% | 120.64% | 88.33% | 81.00% |
| Normalized Basic EPS | 75.50% | 73.02% | 79.04% | 62.49% | 68.56% |
| EPS Diluted | 129.01% | 95.96% | 121.03% | 88.57% | 81.17% |
| Normalized Diluted EPS | 75.67% | 73.21% | 79.29% | 62.45% | 68.39% |
| Average Basic Shares Outstanding | -0.46% | -0.40% | -0.28% | -0.13% | -0.01% |
| Average Diluted Shares Outstanding | -0.57% | -0.52% | -0.40% | -0.09% | 0.07% |
| Dividend Per Share | 15.37% | 15.38% | 15.31% | 15.23% | 15.14% |
| Payout Ratio | -0.49% | -0.41% | -0.48% | -0.39% | -0.36% |